The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1124
February 18, 2002
View Complete Issue         Table of Contents 2019 
Issue 1124
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Activated Protein C (Xigris) For Severe Sepsis
February 18, 2002 (Issue: 1124)
Drotrecogin alfa (activated) (Xigris - Lilly), recombinant human activated protein C, has been approved by the FDA for treatment, in combination with standard therapy, of critically ill adults with severe sepsis and a high risk of death.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1124
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.